Tarix Orphan gets RPD for its rare skin disorder drug

The US Food and Drug Administration has granted a Rare Pediatric Disease (RPD) designation for TXA127 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder.

According to the drug’s developer, US privately-held Tarix Orphan, there are currently no approved therapies for RDEB and treatment is limited to supportive care.

"The RPD designation for TXA127 in RDEB supplements the Orphan Drug Designation previously granted by the FDA in this indication," said Richard Franklin, president and chief executive of Tarix Orphan, adding: "RDEB is a devastating disease. We have been very encouraged by the preliminary animal data we have generated and are looking forward to confirming these results in an additional model through the support of DEBRA International, the European patient organization focused on epidermolysis bullosa."